Please assess the completion status of the following clinical trial:

Trial Title: DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing radiofrequency catheter ablation for scar VT which includes VT secondary to ischemic cardiomyopathy and non-ischemic cardiomyopathy~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug~* Women must not be breastfeeding~* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with Apixaban plus 33 days post-treatment completion~* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and for a total of 93 days post-treatment completion~* Participants must agree to the use of one approved method of contraception~Exclusion Criteria:~* History of cerebral vascular accident/transient ischemic attack (CVA/TIA) in last 3 months~* Cardiac surgery or neurosurgery within 3 months of the intended procedure date~* Any active bleeding~* Severe hypersensitivity reaction to ELIQUIS (including drug hypersensitivity, such as skin rash and allergic reactions)~* Participants cannot have prosthetic heart valves~* History or bleeding and clotting disorders~* Contraindications to Aspirin therapy~* Contraindication to oral anticoagulation~* Patient on an anticoagulant prior to the ablation for other primary indications like atrial fibrillation (AF), deep vein thrombosis (DVT) or a mechanical valve~* Evidence of intracardiac thrombus~* Patient with Creatinine Clearance of \< 30 cc/min~* Participation in another investigational study related to oral anticoagulation, drug and/or device intervention~* Claustrophobic patients~* Implantable Cardioverter Defibrillator (ICD) generator placement before the year 2000~* Has an ICD and is pacing dependent without underlying rhythm upon interrogation at baseline~* Patient has abandoned leads~* Patients who are on p-glycoprotein inducers or inhibitors where the dose of Apixaban cannot be effectively altered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DOAC (Direct Oral Anticoagulant) (Type: EXPERIMENTAL): Participants will be asked to take standard dose approved for stroke prophylaxis
- Aspirin (Type: ACTIVE_COMPARATOR): Participants will be asked to take 81 milligrams by mouth once per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).